Krystal Biotech to Present at 2026 Cantor Global Healthcare Conference
Globe Newswire (Thu, 3-Sep 8:00 AM ET)
Cosmetic Surgery's Next Debate: Rebuild Tissue, Not Fill It
Globe Newswire (Tue, 11-Aug 3:35 PM ET)
Market Chameleon (Mon, 3-Aug 3:54 AM ET)
Krystal Biotech Announces Second Quarter 2026 Financial and Operating Results
Globe Newswire (Mon, 3-Aug 7:00 AM ET)
Krystal Biotech to Report Second Quarter 2026 Financial Results on August 3, 2026
Globe Newswire (Thu, 23-Jul 5:00 PM ET)
Krystal Biotech Set to Join S&P MidCap 400; Tutor Perini and V2X to Join S&P SmallCap 600
PRNewswire (Mon, 20-Jul 5:43 PM ET)
Market Chameleon (Mon, 4-May 5:43 AM ET)
Krystal Biotech Inc is an integrated, commercial-stage biotechnology company focused on the discovery, development, manufacturing, and commercialization of genetic medicines to treat diseases with high unmet medical needs. The company uses its patented HSV-1-based gene therapy platform to create vectors that deliver therapeutic transgenes to target cells. It possesses exclusive rights to develop, manufacture, and commercialize VYJUVEK internationally. The company operates as one operating segment focused on pharmaceutical products and manufactures, markets, and sells VYJUVEK in the United States and markets and sells VYJUVEK in the European Union, and Japan.
Krystal Biotech trades on the NASDAQ stock market under the symbol KRYS.
As of October 5, 2026, KRYS stock price climbed to $327.60 with 68,451 million shares trading.
KRYS has a beta of 0.76, meaning it tends to be less sensitive to market movements. KRYS has a correlation of 0.07 to the broad based SPY ETF.
KRYS has a market cap of $9.58 billion. This is considered a Mid Cap stock.
Last quarter Krystal Biotech reported $119 million in Revenue and $1.79 earnings per share. This fell short of revenue expectation by $-4 million and missed earnings estimates by -$.10.
In the last 3 years, KRYS traded as high as $382.54 and as low as $93.95.
The top ETF exchange traded funds that KRYS belongs to (by Net Assets): VTI, IJH, VB, IWM, XBI.
KRYS has outperformed the market in the last year with a return of +80.3%, while the SPY ETF gained +16.6%. However, in the most recent history, KRYS shares have underperformed the stock market with its stock returning -12.7% in the last 3 month period and -2.7% for the last 2 week period, while SPY has returned +4.0% and +1.5%, respectively.
KRYS support price is $314.98 and resistance is $329.58 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that KRYS shares will trade within this expected range on the day.